Actively Recruiting
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
Led by VA Office of Research and Development · Updated on 2026-02-27
320
Participants Needed
6
Research Sites
310 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic neuropathic pain (CNP) is disabling. Research on frontline treatments for CNP, shows inconsistent outcomes and dissatisfaction among Veterans. Veterans and clinicians have shown significant interest in cannabis derivatives (THC, CBD) for neuropathic pain control, but there are no well-controlled trials guiding expectations for benefit and adverse outcomes associated with cannabis for CNP. Because Veterans are likely to present with pain and pain-related polymorbidity significantly differing from that of civilians, a well-structured clinical trial of cannabinoids for Veterans with CNP is vital.
CONDITIONS
Official Title
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide written consent
- Veterans 21 years and older at the date of screening
- Meet diagnostic criteria for neuropathic pain as defined by the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (NeuPSIG)
- Meet criteria for persistent, high-impact pain
- Presence of allodynia confirmed by a screening dynamic brush test
- Women of childbearing potential who agree to follow contraceptive requirements
You will not qualify if you...
- Actively engaged in or planning non-pharmacological invasive treatment for pain at enrollment
- Peripheral neuropathy is not the primary cause of neuropathic pain
- Hypersensitivity to THC, CBD, or THC/CBD
- Cannabis use during screening phase confirmed by positive urine test for THC-COOH
- Unwilling to avoid cannabis or cannabis-based products throughout the study
- Diagnosis of Cannabis Use Disorder in the past 6 months
- Current diagnosis of cannabis use disorder, substance use disorder, or serious psychiatric disorders
- Changes greater than 20% in pain medication or non-pharmacological treatment from 4 weeks before screening until study completion
- Opioid dose over 400 mg morphine milligram equivalent
- Pregnant, breastfeeding, or intending pregnancy within 12 weeks from enrollment
- Current unstable or concerning medical conditions increasing risk or preventing protocol adherence
- Need for immediate psychiatric hospitalization
- Enrolled in a medical marijuana program
- Federal employee
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
VA San Diego Healthcare System, San Diego, CA
San Diego, California, United States, 92161-0002
Actively Recruiting
2
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, California, United States, 90073-1003
Active, Not Recruiting
3
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
West Haven, Connecticut, United States, 06516-2770
Actively Recruiting
4
Providence VA Medical Center, Providence, RI
Providence, Rhode Island, United States, 02908-4734
Actively Recruiting
5
South Texas Health Care System, San Antonio, TX
San Antonio, Texas, United States, 78229-4404
Actively Recruiting
6
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States, 98108-1532
Terminated
Research Team
C
Courtney C DiCocco
CONTACT
M
Mohini Ranganathan, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here